Clinical Trial Update: Evaluation of the Irinotecan/Bevacizumab Association for Naive Unresectable Glioblastoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the combination of irinotecan and bevacizumab for patients with naive unresectable glioblastoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Bevacizumab (Avastin) (bevacizumab)
• Irinotecan (Camptosar) (Irinotecan)

Snippet

Sponsor: Centre Georges Francois Leclerc | Conditions: Naive Unresectable Glioblastoma | Phase 2 | Status: COMPLETED